UPB Upstream Bio14.70-13.11 (-47.1%)
After Hours:0.00-14.70 (-100.0%)
Premarket Decliner
UPB Upstream Bio27.81+1.69+6.5%
Premarket:19.49-8.32 (-29.9%)
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
Globe NewswireWed, 11-Feb 6:00 AM
After Hours Gainer
After Hours:32.00+4.19 (+15.1%)
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
Globe NewswireTue, 10-Feb 6:00 PM
After Hours:31.00+3.19 (+11.5%)
UPB Upstream Bio27.59+1.47 (+5.6%)
UPB Upstream Bio31.00-1.50 (-4.6%)
